Lymphocyte subsets in renal transplant recipients with de novo genitourinary malignancies

被引:3
|
作者
Guichard, Guillaume [1 ,5 ]
Rebibou, Jean Michel [2 ,4 ,5 ]
Ducloux, Didier [2 ,5 ]
Simula-Faivre, Dominique [3 ]
Tiberghien, Pierre [3 ,6 ]
Chalopin, Jean Marc [2 ,5 ]
Bittard, Hugues [1 ,5 ]
Saas, Philippe [4 ,6 ]
Kleinclauss, Francis [1 ,3 ,4 ,5 ]
机构
[1] Univ Hosp St Jacques, Dept Urol & Renal Transplantat, FR-25000 Besancon, France
[2] Univ Hosp St Jacques, Dept Nephrol & Renal Transplantat, FR-25000 Besancon, France
[3] Univ Hosp St Jacques, Ctr Invest Clin Integre Biotherapies, FR-25000 Besancon, France
[4] Univ Franche Comte, INSERM U645, F-25030 Besancon, France
[5] Univ Franche Comte, IFR 133, F-25030 Besancon, France
[6] Etablissment Francais Sang Bourgogne Franche Comt, Plateforme BioMonitoring, Besancon, France
关键词
renal transplantation; cancer; lymphopenia;
D O I
10.1159/000127337
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The incidence of genitourinary tumors (GUT) in renal transplant recipients (RTR) is higher than in the general population. We previously reported that CD4 lymphocytopenia is associated with a high incidence of skin cancer in RTR. Here, we investigate whether persistent CD4 T cell lymphopenia is associated with GUT occurrence. Patients and Methods: A total of 433 patients were included in this study. All patients underwent annually systematic lymphocyte subset (CD3, CD4, CD8, CD19) determination by flow cytometry. Results and Conclusion: During the follow-up period, 13 patients developed GUT: 6 patients a prostate adenocarcinoma (incidence 0.06%/year) and 7 patients a renal cell carcinoma (incidence 0.07%/ year). The patients with GUT were older than those without. Both groups did not differ in posttransplant duration, dialysis mode and duration, induction regimen, or acute rejection history. No persistent CD4 lymphopenia was observed in the patients with GUT. Although CD4 T cell lymphopenia is associated with skin cancer in long-term RTR, it did not appear to be a risk factor for GUT. This suggests that other factors encountered in the setting of kidney transplantation (e. g., immunosuppressive drugs, end-stage renal failure, etc.) favor the development of GUT in RTR. Copyright (C) 2008 S. Karger AG, Basel.
引用
收藏
页码:257 / 263
页数:7
相关论文
共 50 条
  • [41] De novo cancer in transplant recipients
    Kim, MS
    Kim, SI
    Kim, YS
    Oh, CK
    Park, K
    TRANSPLANTATION PROCEEDINGS, 1996, 28 (03) : 1651 - 1652
  • [42] De novo internal malignancies in liver transplant recipients: Association with donor and recipient characteristics
    Moreno, R
    Benlloch, S
    Berenguer, M
    Prieto, M
    San-juan, F
    LIVER TRANSPLANTATION, 2003, 9 (06) : C24 - C24
  • [43] De novo renal cell carcinoma of native and graft kidneys in renal transplant recipients
    Tsaur, Igor
    Obermueller, Nicholas
    Jonas, Dietger
    Blaheta, Roman
    Juengel, Eva
    Scheuermann, Ernst-Heinrich
    Kachel, Heinz-Georg
    Karalis, Athanasios
    Probst, Michael
    BJU INTERNATIONAL, 2011, 108 (02) : 229 - 234
  • [44] COMPARISON OF LYMPHOCYTE SUBSETS OF PERIPHERAL-BLOOD AND GRAFTS IN RENAL-TRANSPLANT RECIPIENTS
    TASHIRO, M
    AIKAWA, A
    SATO, I
    KIMURA, I
    IWASHITA, Y
    ARAI, K
    OHARA, T
    HIRATA, K
    HASEGAWA, A
    TRANSPLANTATION PROCEEDINGS, 1989, 21 (01) : 1859 - 1860
  • [45] Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or De Novo malignancy
    Rayes, N
    Bechstein, WO
    Tullius, SG
    Nüssler, NC
    Naumann, U
    Jonas, S
    Neuhaus, R
    Serke, S
    Neuhaus, P
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) : 1846 - 1847
  • [46] Study of a new generic cyclosporine, Consupren, in de novo renal transplant recipients
    Zafar, MN
    Ahmed, E
    Alam, A
    Akhtar, F
    Zafar, H
    Hashmi, A
    Naqvi, A
    Rizvi, A
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (06) : 2480 - 2481
  • [47] De Novo Use of Everolimus With Elimination or Minimization of Cyclosporine in Renal Transplant Recipients
    Novoa, P. A.
    Grinyo, J. M.
    Ramos, F. J. P.
    Errasti, P.
    Franco, A.
    Aldana, G.
    Pefaur, J.
    Marti-Cuadros, A. M.
    Otero, A. B.
    Saval, N.
    Oppenheimer, F.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (09) : 3331 - 3339
  • [48] PHARMACOKINETICS OF EVEROLIMUS WHEN COMBINED WITH TACROLIMUS IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Rostaing, L.
    Pascual, J.
    Machein, U.
    Kovarik, J. M.
    TRANSPLANT INTERNATIONAL, 2011, 24 : 253 - 253
  • [49] De novo sirolimus-based regimen in Thai renal transplant recipients
    Townamchai, N.
    Avihingsanon, Y.
    Praditpornsilpa, K.
    Tungsanga, K.
    Eiam-Ong, S.
    TRANSPLANTATION PROCEEDINGS, 2008, 40 (07) : 2206 - 2208
  • [50] Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric renal transplant recipients
    Zhao, W.
    Elie, V.
    Roussey, G.
    Brochard, K.
    Niaudet, P.
    Deschenes, G.
    Cochat, P.
    Cloarec, S.
    Andre, J. L.
    Tsimaratos, M.
    Bensman, A.
    Fakhoury, M.
    Jacqz-Aigrain, E.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 101 - 101